Feeds:
Posts
Comments

Archive for the ‘Biomarkers’ Category

MEDICAL NEWS TODAY: The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. READ MORE>

The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article in The Journal of the National Cancer Institute.

if the biomarker is affected by a non-cancer disease, its utility for cancer detection may be compromised. For example, the prostate-specific antigen (PSA) biomarker, which is used to detect prostate cancer, is also elevated in benign prostatic hyperplasia.

Read Full Post »

URO TODAY: Emerging urine tests should help in both early diagnosis of prostate cancer and identifying aggressive tumors for radical treatment. READ MORE>

Read Full Post »

SCIENCE-CENTRIC.COM:  A study of prostate risk factors in Japanese men seems to reinforce the idea that discovered variants are often simply population-specific markers that need far more study to confirm as functional culprits. READ MORE>

Read Full Post »

URO TODAY: Australian researchers have identified a novel transcription factor in metastatic prostate cancer designated IV07, which appears to be involved in the regulation and co-ordination of multiple cancer promoting pathways. READ MORE>

The identification of IV07 may provide an important new therapeutic target in the prevention or treatment of metastatic disease and possibly may serve as a prognostic biomarker for cancer progression.

Read Full Post »

JUNE 25: NEW PROSTATE CANCER INFOLINK: “We need to start really focusing on whether this or that genetic variation has any prognostic impact on prostate cancer risk before we waste a lot of money chasing associations that have minimal likelihood of prognostic value,” writes Mike Scott. READ MORE>

Read Full Post »

JUNE 21: URO TODAY: The human genome project and high throughput gene expression profiling has recently yielded several promising molecular biomarkers for prostate cancer detection beyond PSA or PSA modifications. READ MORE>

Read Full Post »

JUNE 19: DRUGS.COM: A new marker for advanced prostate cancer and metastasis, or spread, of the disease has been identified by US researchers. Analysis of prostate tissue from men with localised prostate cancer revealed that the men had significantly decreased levels of a stromal protein called caveolin-1. The researchers also found that the protein was not present in tumour tissue from men with metastatic prostate cancer. READ MORE>

Read Full Post »

JUNE 13: URO TODAY: WAVE3 is pivotal in controlling the invasiveness of prostate cancer cells, according to a new study at Cardiff University School of Medicine in the UK .

Wiskott-Aldrich syndrome verprolin-homologous 3 (WAVE3) belongs to Wiskott-Aldrich syndrome family proteins, which, along with other members, play a critical role in the regulation of actin polymerization and cell motility. We investigated the expression pattern and the effects of manipulating endogenous WAVE3 expression in prostate cancer cells.

Further work is needed to assess WAVE3 as a potential marker for predicting tumour aggressiveness. READ MORE>

Read Full Post »

JUNE 6: URO TODAY: Two ongoing, randomized controlled trials are examining whether screening reduces the risk of prostate cancer-related mortality, and the results of these studies are expected soon. Although it has its limitations, PSA still remains the best-studied marker for the detection of prostate cancer. READ MORE>

Read Full Post »

JUNE 5: WEB MD:  A blood test that characterises each prostate tumour by its unique genetic fingerprint may help pinpoint which men actually have prostate cancer, researchers say. READ MORE>

Read Full Post »

Older Posts »

Follow

Get every new post delivered to your Inbox.

Join 26 other followers